Truist Financial Cuts Integra LifeSciences (NASDAQ:IART) Price Target to $19.00

Integra LifeSciences (NASDAQ:IART) had its price objective cut by Truist Financial from $26.00 to $19.00 in a report published on Friday,Benzinga reports. They currently have a hold rating on the life sciences company’s stock.

Separately, Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Monday, March 31st. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences has an average rating of “Hold” and an average price target of $22.71.

Integra LifeSciences Stock Down 2.5 %

Shares of NASDAQ IART opened at $16.99 on Friday. The business has a fifty day moving average of $22.28 and a two-hundred day moving average of $22.34. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. Integra LifeSciences has a 52-week low of $15.95 and a 52-week high of $33.04. The stock has a market cap of $1.31 billion, a PE ratio of -188.76, a PEG ratio of 0.73 and a beta of 1.24.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 earnings per share. As a group, equities research analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC grew its stake in shares of Integra LifeSciences by 3,595.1% during the 1st quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company’s stock worth $5,140,000 after acquiring an additional 22,721 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Integra LifeSciences in the fourth quarter valued at $1,721,000. Paradigm Capital Management Inc. NY increased its stake in Integra LifeSciences by 170.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock valued at $32,457,000 after buying an additional 901,600 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Integra LifeSciences by 16.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 198,642 shares of the life sciences company’s stock worth $4,505,000 after buying an additional 28,457 shares in the last quarter. Finally, Woodline Partners LP acquired a new position in shares of Integra LifeSciences during the 4th quarter worth about $2,512,000. Institutional investors and hedge funds own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.